Group 1 - The annual general meeting of Zhejiang Longsheng Group Co., Ltd. was held on May 30, 2025, with no resolutions rejected [2] - The meeting was presided over by Chairman Ruan Weixiang, and all procedures complied with the Company Law and Articles of Association [2][3] - All proposals presented at the meeting, including the 2024 annual financial report and profit distribution plan, were approved [4][5][6] Group 2 - The company signed a share purchase agreement to acquire 37.57% of the issued share capital of DyStar Global Holdings (Singapore) Ltd. from KIRI Industries Limited for USD 69,654.78 thousand [21][23] - The transaction is not classified as a related party transaction or a major asset restructuring and falls within the board's authority [22] - The acquisition aims to resolve ongoing litigation and make DyStar a wholly-owned subsidiary, enhancing the company's profitability [23][34] Group 3 - The financial evaluation of DyStar estimated its enterprise value between USD 1.178 billion and USD 1.288 billion, with a projected value of 100% shares between USD 1.791 billion and USD 1.901 billion [26][27] - The purchase price was determined based on fair negotiations and market valuation methods, including EBITDA multiples [26] - The acquisition is expected to increase the company's liabilities but is aligned with its strategic goal of becoming a leading specialty chemicals producer [34]

Core Viewpoint - The company is responding to an inquiry from the Shenzhen Stock Exchange regarding the sale of its 100% stake in Beijing Jiawo Zhencheng Technology Co., Ltd. for 1 yuan, despite the assessed value being -54.75 million yuan, raising questions about accounting treatment and compliance [2][3]. Accounting Treatment and Compliance - The accounting treatment for the sale is based on the "Accounting Standards for Business Enterprises No. 2 - Long-term Equity Investments," which states that the difference between the book value and the actual sale price should be recognized as investment income [2]. - The transaction is deemed to have a capital contribution nature, as the company benefits unilaterally from the transaction, aligning with relevant accounting standards and regulatory guidelines [3]. Specific Accounting Treatment - Individual Financial Statements: - Termination of long-term equity investment in Jiawo Zhencheng with a total impairment provision of 2.35 billion yuan [4]. - Consolidated Financial Statements: - Adjustments include the termination of recognition of Jiawo Zhencheng's assets and liabilities, with total liabilities of 9.69 billion yuan and total assets of 8.74 billion yuan [5]. Financial Statement Impact - If the transaction is completed on December 31, 2024, the individual financial statements will reflect an increase in net assets by 1 yuan, while the consolidated financial statements will show an increase in net assets by 9.41 billion yuan and an increase in net assets attributable to the parent company by 7.25 billion yuan [5]. Audit Firm's Verification Opinion - The audit firm confirms that the accounting treatment for the transaction is in compliance with accounting standards and regulatory requirements, and the financial statement impacts are accurately disclosed [6].